QIV
Biological
Seqirus USA Inc
Total Payments
$3.0M
Transactions
341
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $3.0M | 341 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $3.0M | 341 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age | Seqirus USA Inc | $3.0M | 0 |
Top Doctors Receiving Payments for QIV
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Diamond Bar, CA | $3.0M | 341 |
Ad
Manufacturing Companies
- Seqirus USA Inc $3.0M
Product Information
- Type Biological
- Total Payments $3.0M
- Total Doctors 0
- Transactions 341
About QIV
QIV is a biological associated with $3.0M in payments to 0 healthcare providers, recorded across 341 transactions in the CMS Open Payments database. The primary manufacturer is Seqirus USA Inc.
Payment data is available from 2017 to 2017. In 2017, $3.0M was paid across 341 transactions to 0 doctors.
The most common payment nature for QIV is "Unspecified" ($3.0M, 100.0% of total).
QIV is associated with 1 research study, including "A Study to Evaluate the Immunogenicity and Safety of Seqirus Quadrivalent Influenza Vaccine (QIV) in a Pediatric Population 6 Months Through 59 Months of Age" ($3.0M).